ALMS | tickerfilter.com

Fundamental analysis

42%

Profitability 35%

Dept financing 27%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.65%

1 Month

18.85%

3 Months

-10.51%

6 Months

409.98%

1 Year

454.73%

2 Year

80.60%

Key data

Stock price

$24.02

P/E Ratio

N/A

DAY RANGE

$23.58 - $25.63

EPS

-$5.37

52 WEEK RANGE

$2.76 - $30.60

52 WEEK CHANGE

$480.19

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

127.199 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-15-2025

BETA

1.20

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,302,097

AVERAGE 30 VOLUME

$1,564,673

Company detail

CEO: Martin Babler
Region: US
Website: www.alumis.com
Employees: 0
IPO year: 2024

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

ALMS - Alumis Inc.